Novavax (NVAX) Q2 2026 earnings summary

Executive summary

• Strategic transformation centers on partnerships, capital-efficient innovation, and a lean operating model, with major alliances including Sanofi and Pfizer advancing both infectious disease and oncology programs.

• Four of the top 10 global pharma companies have Matrix-M licensing or MTA agreements, with Pfizer providing a $30M upfront and up to $500M in milestones.

• Sanofi partnership is progressing with advanced regulatory discussions, expanded commercial launches in multiple countries, and significant milestone and royalty potential.

• Internal pipeline is advancing, notably with a differentiated C. difficile vaccine candidate moving toward clinical entry and growing oncology focus.

• Operating expenses have been reduced by over 80% from peak, with further reductions and restructuring ongoing.

Financial highlights

• Q2 2026 total revenue was $57M, down from $239M in Q2 2025, mainly due to lower milestone and licensing payments.

• Product sales reached $19M, up 76% year-over-year, driven by Matrix-M demand and partner sales.

• Net loss for Q2 2026 was $53M; cash and equivalents at quarter-end totaled $743M.

• R&D and SG&A expenses decreased 36% year-over-year on a non-GAAP basis.

• Full-year 2026 adjusted revenue guidance raised to $235M–$275M, with midpoint at $255M.

Outlook and guidance

• Expect $75M Sanofi tech transfer milestone in mid-2027, extending cash runway into 2029.

• Potential $125M milestone upon phase III initiation of Sanofi's combination vaccine.

• Majority of 2026 revenue expected in Q4, aligned with COVID-19 vaccine season.

• 2026 non-GAAP R&D and SG&A expense guidance is $310M–$340M.

• Targeting non-GAAP profitability as early as 2028 and maintaining at least two years of cash runway.